Every number is sourced.
Every caveat stays.
Obesity medicine, GLP-1s, and cardiovascular prevention. Clinical evidence explained by Michael Albert, MD, for clinicians and curious patients. Free, twice a week.
Get the evidence in your inbox
Understand the trials. Keep the caveats. Obesity medicine and cardiovascular prevention, free, twice a week.
GLP1
+1
Oct 6, 2026
•
10 min read
23.3% Weight Loss in Type 2 Diabetes. Can Patients Stay on Treatment?
In a randomized Phase 2b trial, Lilly’s amylin-plus-tirzepatide combination showed 8.5 percentage points greater estimated weight loss than tirzepatide 15 mg. The open question is how many people can stay on it.
GLP1
+1
Oct 3, 2026
•
18 min read
Glucagon Was the Villain. Amylin Was a Footnote.
A mechanism-first deep dive into the two hormones behind the next obesity drugs: what they do in the liver and the brainstem, and what the trials can and can't confirm.
Who writes this
№ 1
Written by Michael Albert, MD, a board-certified obesity medicine physician.
№ 2
Every number is sourced to the trial, and the caveats are never cut.
№ 3